KDC-MN-1342 – Kodiac biolabs

Our opinion on this compoundNovel, promising

64/100

A dual GLP-1/glucagon agonist with real Phase 3 promise, strongest case in MASH

Look, survodutide is a serious compound in a seriously competitive space. Boehringer Ingelheim and Zealand Pharma built this as a 39-residue lipidated peptide with roughly balanced activity at both GLP-1 and glucagon receptors, and the pharmacokinetic strategy is exactly what you’d expect from this generation of metabolic peptides: a fatty acid chain for serum albumin binding, once-weekly subcutaneous dosing. Familiar architecture, but the glucagon receptor agonism is where the real story is.

Here’s the thing about adding glucagon to GLP-1: it’s not just additive appetite suppression. GLP-1 handles the central appetite and gastric emptying piece, but glucagon receptor agonism specifically drives hepatic fatty acid oxidation and increases whole-body energy expenditure in a way that GLP-1 monoagonists can’t replicate. That combination is what produced approximately 19 percent body weight reduction at 46 weeks in Phase 2 data published in 2024, numbers that land in tirzepatide territory and well ahead of semaglutide’s ceiling.

What we find genuinely compelling here is the MASH angle. Metabolic dysfunction-associated steatohepatitis is a brutal target: large unmet need, a liver disease that’s difficult to reverse, and the glucagon receptor mechanism drives hepatic fat mobilization directly. That’s mechanistically more targeted for MASH than pure GLP-1 agonism or even the GIP/GLP-1 combination in tirzepatide. The SYNCHRONIZE-2 trial is one of the more interesting things in the MASH pipeline right now, and a clean liver histology signal from that program would reposition survodutide decisively above every pure GLP-1 agent in the hepatic disease space.

The honest scoring issue for survodutide is differentiation in the obesity indication. Tirzepatide is approved and defines that category. Retatrutide adds GIP receptor agonism on top of the glucagon and GLP-1 already in survodutide’s profile, with a potentially higher efficacy ceiling. Survodutide doesnt have GIP, and if Lilly’s triple agonist survives Phase 3, that absence matters for the obesity claim. The GIP component in tirzepatide turned out to be important for insulin sensitization and weight loss ceiling; glucagon addresses energy expenditure and hepatic fat clearance but doesnt replicate the same glucose-handling angle.

That said, Phase 3 SYNCHRONIZE obesity data aren’t in yet, and the MASH program is genuinely differentiated from anything tirzepatide or semaglutide is positioned to do. Survodutide also clearly outclasses cotadutide on pharmacokinetic profile. We think this is a compound worth active tracking, especially heading into the 2026 to 2027 regulatory submission window. Strong Phase 2 human data, a coherent dual mechanism with a real hepatic rationale, and unmet-need positioning in MASH. It just isn’t the category-defining move that tirzepatide was when the GIP controversy was still live.

Novelty: 60
Mechanism promise: 70
In-category differentiation: 65
Evidence quality: 58
Translational signal: 68
Research bench value: 58

Rationale Solid Phase 2 human efficacy (~19% weight loss at 46 weeks) and a mechanistically coherent glucagon-driven MASH angle push scores up, but survodutide competes directly with tirzepatide in obesity and lacks GIP receptor agonism; pending Phase 3 readouts keep evidence and translational scores from reaching the high 70s.

GLP-1 and glucagon receptor dual agonist

A long-acting GLP-1 and glucagon receptor dual agonist developed by Boehringer Ingelheim and Zealand Pharma, advanced through Phase 3 in obesity and MASH.

Abstract

Survodutide (BI 456906; SAR-441255; CAS 2403761-22-2 mass) is a long-acting GLP-1 receptor and glucagon receptor dual agonist developed by Boehringer Ingelheim in collaboration with Zealand Pharma. The compound is a 39-residue lipidated peptide based on the glucagon and GLP-1 sequences, with selective potency approximately equivalent at the two receptors and with a fatty acid chain modification enabling once-weekly subcutaneous administration through serum albumin binding (the same pharmacokinetic strategy used by semaglutide, liraglutide, and tirzepatide). The dual-agonist mechanism produces synergistic effects on body weight: GLP-1 receptor agonism reduces appetite and slows gastric emptying through hypothalamic and brainstem pathways (the dominant mechanism shared with semaglutide and other GLP-1 monoagonists), while glucagon receptor agonism increases hepatic fatty acid oxidation and energy expenditure, mobilizing hepatic and visceral fat in a manner not achieved by GLP-1 monoagonism. Phase 2 obesity results published in 2024 reported up to approximately 19 percent body weight reduction at 46 weeks at the highest dose, similar to the magnitude observed with tirzepatide and substantially greater than semaglutide. The compound is in active Phase 3 development in obesity (SYNCHRONIZE program) and MASH (SYNCHRONIZE-2; metabolic dysfunction-associated steatohepatitis) with anticipated regulatory submissions in 2026 to 2027. Side effect profile parallels other GLP-1-class agents (nausea, vomiting, diarrhea, occasional gastroparesis) with the additional consideration of glucagon-related effects (modest heart rate elevation, occasional hypoglycemia masked by reduced insulin sensitivity, and consideration of bilirubin elevation). Survodutide is distinct from retatrutide (Eli Lilly’s triple GLP-1/GIP/glucagon agonist) in lacking GIP receptor agonism and from cotadutide (AstraZeneca’s GLP-1/glucagon dual) in pharmacokinetic profile and clinical positioning.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1342Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1342

Survodutide

Abstract

Read the full monograph